| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
We used oxaliplatin resistant clones derived from DLD1 and HCT116 for this study. The clones derived from HCT116 were resistant to 5-FU, CPT-11, and TFT other than OHP, although those from DLD1 were resistant to OHP alone. We compared gene expressions between HCT116 and OHP resistant clones in cell culture and tumor by microarray analysis. LMO7,LTBP1, and WWWC3 were considered as molecular marker when exon sequence data was combined with array data. AKR1C1 and AKR1C3 were considered as molecular marker, when function of the candidate genes were included for consideration.
|
